Company / Capital Expenditures
GT Biopharma, Inc. Capital Expenditures History
FY2012-FY2017 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
-
FY2017
5-year range
$0 / $6.0K
FY2013-FY2017
Trend
-100.0%
vs FY2016
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $6,000 to $0 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2017, capital expenditures decreased 100.0% year-over-year.
- Peak capital expenditures was recorded in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2020 | - | - |
| FY2017 | $0 | -100.0% |
| FY2016 | $1.0K | -83.3% |
| FY2015 | $6.0K | - |
| FY2014 | $0 | -100.0% |
| FY2013 | $2.0K | - |
| FY2012 | $0 | - |
| FY2011 | - | - |
As of FY2017 · SEC 10-K · Updated Jun 24, 2026